Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alirocumab versus placebo in adults with heterozygous familial hypercholesterolemia and elevated LDL-C despite lipid-modifying therapy
NL-OMON39914Phase 3Active, not recruiting
- Sponsor
- Sanofi
- Start
- Dec 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in familial hypercholesterolemia (FH) comparing Alirocumab plus background lipid-modifying therapy with Placebo plus background lipid-modifying therapy (2 arms). Started Dec 2012; status: active, not recruiting.
02
Drugs
alirocumab
03
Conditions
familial hypercholesterolemia (FH)
Beyond the preview
Go deeper on NL-OMON39914.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39914.